Lionheart Health, Inc., through Leonhardt Ventures LLC, has filed a provisional patent application for a bioelectric stimulation platform designed to enhance peptide uptake and biological effectiveness across multiple delivery methods. The technology addresses critical challenges in peptide delivery, where current methods result in significant losses: up to 70% of intravenous delivery is lost, while oral and topical deliveries can lose up to 99.9% of their effectiveness.
The platform focuses on improving absorption and signaling efficiency across healthspan-related pathways, including klotho, sirtuins, sestrins, apelin, LIM, BDNF, SDF1, PDGF, VEGF, and S100a proteins. Early experimental data indicates improvements of up to 300 percent in peptide efficacy and uptake, potentially enabling lower dosing while maintaining or increasing therapeutic impact. This advancement could make peptide-based longevity interventions more efficient, predictable, and scalable.
The patent builds on decades of bioelectric medicine research conducted by Leonhardt Ventures and expands Lionheart Health's proprietary platform for modulating cellular environments to optimize peptide and protein activity. The company, recognized for its leadership in klotho-based longevity research and recently named a Top 40 semifinalist in the XPRIZE Healthspan competition, holds multiple issued patents related to klotho technologies.
Key mechanisms described in the patent include enhanced transmembrane transport through bioelectric fields that modulate membrane potential, improved barrier permeability through temporary changes to tight junction behavior in the gut and skin, receptor sensitization that increases receptor availability and responsiveness, and intracellular trafficking optimization that reduces peptide degradation. The technology also enables dose efficiency amplification, allowing for lower peptide doses while maintaining biological effects.
Howard J. Leonhardt, Executive Chairman, Inventor and co-CEO of Lionheart Health, Inc. and CEO of Leonhardt Ventures LLC, stated that combining peptides with bioelectric signaling could unlock significantly greater biological impact at lower doses across multiple administration routes. The patent claims encompass oral, topical, and injectable peptide delivery enhanced by targeted bioelectric stimulation, with special emphasis on peptides that enhance Klotho activity, a protein closely linked to aging regulation and cellular resilience.
The newly filed intellectual property strengthens Lionheart Health's position at the intersection of bioelectric medicine and peptide therapeutics, creating opportunities for next-generation longevity and wellness protocols, licensed clinical and research applications, and integration into future devices and programs. The company plans to incorporate the technology into selected upcoming healthspan initiatives and investigational protocols while pursuing strategic partnerships and licensing opportunities. More information about the company's work can be found at http://www.lionhearthealthstim.com and http://www.LionheartLongevity.com.
Potential applications include supporting muscle, brain, immune, metabolic, aesthetic, cardiovascular, and regenerative health. The company's studies include combining bioelectric stimulation enhanced peptides with various therapies such as PEMF, electromagnetic high intensity RF, LED light, vibrational therapy, sauna, cold plunge, hyperbaric oxygen, BodStim TM enhanced exercise, and customized supplements. This comprehensive approach represents a significant advancement in making advanced peptide-based longevity interventions more accessible and effective for broader applications in healthspan extension and regenerative medicine.
